Table 1.
Risk of prostate cancer by cumulative days’ supply of haloperidol and comparator drug (excludes users of both haloperidol and comparator drugs)a
| Days’ supply | Haloperidol only | Comparator only | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of cases | No. of controls | Initial model OR 95% CI)b | Full model OR (95% CI)c | No. of cases | No. of controls | Initial model OR (95% CI)b | Full model OR (95% CI)c | |
| No use | 39,553 | 1,962,602 | 1 [Reference] | 1 [Reference] | 39,553 | 1,962,602 | 1 [Reference] | 1 [Reference] |
| < 1 y | 30 | 2008 | 0.69 (0.48–0.99) | 0.73 (0.51–1.05) | 166 | 8891 | 0.87 (0.75–1.02) | 0.83 (0.71–0.97) |
| At least 1 y | 4 | 576 | 0.32 (0.12–0.84) | 0.38 (0.14–1.01) | 100 | 5847 | 0.80 (0.66–0.98) | 0.75 (0.61–0.91) |
| At least 2 yd | 4 | 352 | 0.54 (0.20–1.44) | 0.66 (0.24–1.76) | 65 | 3639 | 0.84 (0.66–1.08) | 0.80 (0.62–1.02) |
a
At least 2 years is included in the at least 1-year group.
b
Conditional on matching factors (birth year, year of joining program, and follow-up time) and controlled for race/ethnicity.
c
Additionally controlled for number of medical clinic visits 1 to 2 years before the index date (1, 2, ≥ 3 vs 0), number of prostate-specific antigen tests within 3 years before the index date (≥ 1 vs 0), and diagnosis of benign prostatic hyperplasia before the index date (yes vs no).
d
There were no cases for the haloperidol-only users with 1 to 2 years of days’ supply.
CI = confidence interval; OR = odds ratio.